A bill to prohibit contracting with certain biotechnology providers.
Latest action · Dec 4, 2023 Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedDec 4, 2023
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
Specifically, the bill prohibits executive agencies from (1) procuring, obtaining, extending, or renewing a contract to procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern; or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.
A biotechnology company of concern includes BGI Group, MGI Group, Complete Genomics, any subsidiary, parent affiliate, or successor of such entities, and any entity that
- is subject to the jurisdiction, direction, or control of a foreign adversary;
- operates primarily in the biotechnology industry; and
- the Department of Defense (DOD) deems to pose a risk to national security.
DOD must determine, within 90 days after this bill's enactment, whether WuXi AppTec, Axbio, and any subsidiary, affiliate, or successor of such entities, or any other entity headquartered in or organized under the laws of China, is a biotechnology company of concern.
Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.
Cosponsors
Members who signed on, in the order they did.
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Homeland Security and Governmental Affairs Committee | Referred Dec 4, 2023 |
Actions 2
Everything that happened, newest first.
- Dec 4, 2023Introduced in Senate
- Dec 4, 2023Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Titles 1
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to prohibit contracting with certain biotechnology providers.
Subjects
Assigned by the Library of Congress. Policy area: Government Operations and Politics.
Text 1
Each version as it was printed, newest first.
- Dec 4, 2023Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
